Histone Demethylase Inhibitor

Histone Demethylase Inhibitors (204):

Cat. No.	Product Name	Effect	Purity

HY-101451

PBIT	Inhibitor	99.46%
PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes. PBIT inhibits JARID1B (KDM5B or PLU1) histone demethylase with an IC₅₀ of about 3 μM . PBIT also inhibits JARID1A and JARID1C with IC₅₀s of 6 μM and 4.9 μM, respectively.

HY-139601

KDM2B-IN-4	Inhibitor	99.61%
KDM2B-IN-4 (Compound 182b) is a histone demethylase KDM2B inhibitor with an IC₅₀ of 1.12 nM. KDM2B-IN-4 can be used for the research of hyperproliferative diseases such as cancers.

HY-109169

Bomedemstat	Inhibitor	98.23%
Bomedemstat (IMG-7289) is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis.

HY-19333

OG-L002	Inhibitor	99.55%
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC₅₀ of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC₅₀s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes.

HY-100421A

CPI-455 hydrochloride	Inhibitor	99.95%
CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents.

HY-139560

KDM2B-IN-1	Inhibitor	99.19%
KDM2B-IN-1 (example 32) is a histone demethylase (kdm2b) inhibitor with an IC₅₀ of 0.016 nM. KDM2B-IN-1 can be used for hyperproliferative diseases research.

HY-138691A

JQKD82 trihydrochloride	Inhibitor	99.89%
JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma.

HY-122635A

T-448	Inhibitor	98.86%
T-448 is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC₅₀ of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons.

HY-100764

YUKA1	Inhibitor	99.15%
YUKA1 is a potent and cell permeable Lysine demethylase 5A (KDM5A) inhibitor, with an IC₅₀ of 2.66 μM. YUKA1 has less inhibitory active on KDM5C (IC₅₀ = 7.12 μM) and is inactive on KDM5B, KDM6A or KDM6B. YUKA1 can increase H3K4me3 levels and inhibit cell proliferation. YUKA1 can be used for the research of cancer, such as lung and breast cancers.

HY-149091

KDM5B-IN-4	Inhibitor	99.68%
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC₅₀ of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs.

HY-113039

L-2-Hydroxyglutaric acid	Inhibitor
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively.

HY-W025799

N-Benzylideneaniline	Inhibitor	99.97%
N-Benzylideneaniline is an inhibitor of xylinostilbene-α,β-dioxygenase (LSD).

HY-15648C

GSK-J5	Inhibitor	99.33%
GSK-J5 is a potent inhibitor of Schistosome and worm. GSK-J5 increases schistosomula mortality and adult worm motility and mortality, as well as egg oviposition, in a dose- and time-dependent manner.

HY-117226A

GSK 690 Hydrochloride	Inhibitor	98.58%
GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a K_d value of 9 nM and a biochemical IC₅₀ of 37 nM.

HY-149213

LSD1-IN-24	Inhibitor	99.20%
LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC₅₀ = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research.

HY-162301

P3FI-63	Inhibitor	98.35%
P3FI-63 is a KDM3B inhibitor with a IC₅₀ value of 7 μM. P3FI-63 has antitumor activity.

HY-141677

INCB059872	Inhibitor	98.06%
INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia.

HY-132198

JMJD7-IN-1	Inhibitor	98.57%
JMJD7-IN-1 is a potent JMJD7 inhibitor, with an IC₅₀ of 6.62 μM. JMJD7-IN-1 shows good inhibitory activity against cells expressing a high level of JMJD7.

HY-141677A

INCB059872 dihydrochloride	Inhibitor	99.18%
INCB059872 dihydrochloride is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 dihydrochloride can be used for the research of myeloid leukemia.

HY-123419

CPI-4203	Inhibitor	99.0%
CPI-4203 is a potent KDM5A inhibitor with an IC₅₀ of 250 nM. CPI-4203 is competitive with 2-oxoglutarate (2-OG). CPI-4203 is structurally related to CPI-455 (HY-100421) but is less potent.

Name
Email *

	Sorry, but the email address you supplied was invalid.